Document Type: Research Articles
Yale New Haven Health at Bridgeport Hospital, Department of Radiology, 267 Grant Street, Bridgeport, CT, USA
St. Vincent's Medical Center , Department of Radiology, 2800 Main Street, Bridgeport, CT, USA
SUNY Upstate Medical University, Syracuse NY, USA
SUNY Upstate Medical University, Department of Radiology, 750 East Adams Street, Syracuse, NY 13210, USA
Objective: Comparison of the accuracy of MR perfusion and 18-FDG-PET for differentiating tumor progression from nonneoplastic contrast-enhancing tissue. Methods and Materials: Retrospective review of MR perfusion and 18-FDG-PET in 23 cases of primary brain tumors (17 high grade and 6 low grade glial neoplasms) and 5 cases of metastatic lesions with enhancing lesions on post-treatment MRI was performed. The accuracy of MR perfusion versus 18-FDG-PET for distinguishing between nonneoplastic contrast-enhancing tissue and tumor recurrence was assessed. Results: Both CBV (p<0.004) and SUV (p<0.02) are higher in recurrent tumors than necrosis. MR perfusion has an accuracy of 94.5% for differentiating between tumor recurrence and necrosis, while 18-FDG-PET has an accuracy of 85.1% for differentiating between tumor recurrence and nonneoplastic contrast-enhancing tissue. Conclusion: Overall, recurrent tumor demonstrates significantly higher CBV and SUV than nonneoplastic contrast-enhancing tissue. However, MR perfusion appears to be more accurate than FDG PET for distinguishing the two entities.